BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 32850388)

  • 1.
    Arantes LMRB; Cruvinel-Carloni A; de Carvalho AC; Sorroche BP; Carvalho AL; Scapulatempo-Neto C; Reis RM
    Front Oncol; 2020; 10():1275. PubMed ID: 32850388
    [No Abstract]   [Full Text] [Related]  

  • 2. Distinct TERT promoter C228T and C250T mutations in a patient with an oligodendroglioma: A case report.
    Ishi Y; Okada H; Okamoto M; Motegi H; Tanaka S; Mitsuhashi T; Yamaguchi S
    Neuropathology; 2021 Jun; 41(3):236-242. PubMed ID: 33899270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory Single Nucleotide Polymorphism Increases TERT Promoter Activity in Thyroid Carcinoma Cells.
    Hirokawa T; Arimasu Y; Chiba T; Nakazato Y; Fujiwara M; Kamma H
    Pathobiology; 2020; 87(6):338-344. PubMed ID: 33227798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
    Wang N; Liu T; Sofiadis A; Juhlin CC; Zedenius J; Höög A; Larsson C; Xu D
    Cancer; 2014 Oct; 120(19):2965-79. PubMed ID: 24898513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of promoter mutations in the TERT gene in oral cavity squamous cell carcinoma.
    Chang KP; Wang CI; Pickering CR; Huang Y; Tsai CN; Tsang NM; Kao HK; Cheng MH; Myers JN
    Head Neck; 2017 Jun; 39(6):1131-1137. PubMed ID: 28230921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors.
    Liu T; Brown TC; Juhlin CC; Andreasson A; Wang N; Bäckdahl M; Healy JM; Prasad ML; Korah R; Carling T; Xu D; Larsson C
    Endocr Relat Cancer; 2014 Jun; 21(3):427-34. PubMed ID: 24803525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TERT promoter mutation in adult granulosa cell tumor of the ovary.
    Pilsworth JA; Cochrane DR; Xia Z; Aubert G; Färkkilä AEM; Horlings HM; Yanagida S; Yang W; Lim JLP; Wang YK; Bashashati A; Keul J; Wong A; Norris K; Brucker SY; Taran FA; Krämer B; Staebler A; van Meurs H; Oliva E; Shah SP; Kommoss S; Kommoss F; Gilks CB; Baird DM; Huntsman DG
    Mod Pathol; 2018 Jul; 31(7):1107-1115. PubMed ID: 29449679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TERT C228T mutation in non-malignant bladder urothelium is associated with intravesical recurrence for patients with non-muscle invasive bladder cancer.
    Hayashi Y; Fujita K; Nojima S; Tomiyama E; Matsushita M; Koh Y; Nakano K; Wang C; Ishizuya Y; Kato T; Hatano K; Kawashima A; Ujike T; Uemura M; Imamura R; Morii E; Nonomura N
    Mol Oncol; 2020 Oct; 14(10):2375-2383. PubMed ID: 32533903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in Detecting Low Prevalence Somatic
    da Costa VR; Bim LV; Pacheco E Silva LDP; Colloza-Gama GA; Bastos AU; Delcelo R; Oler G; Cerutti JM
    Front Endocrinol (Lausanne); 2021; 12():643151. PubMed ID: 33776938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low Prevalence of Somatic TERT Promoter Mutations in Classic Papillary Thyroid Carcinoma.
    Jeon MJ; Kim WG; Sim S; Lim S; Kwon H; Kim TY; Shong YK; Kim WB
    Endocrinol Metab (Seoul); 2016 Mar; 31(1):100-4. PubMed ID: 26676331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paraganglia.
    Papathomas TG; Oudijk L; Zwarthoff EC; Post E; Duijkers FA; van Noesel MM; Hofland LJ; Pollard PJ; Maher ER; Restuccia DF; Feelders RA; Franssen GJ; Timmers HJ; Sleijfer S; de Herder WW; de Krijger RR; Dinjens WN; Korpershoek E
    Endocr Relat Cancer; 2014 Aug; 21(4):653-61. PubMed ID: 24951106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TERT promoter mutations in primary and secondary glioblastomas.
    Nonoguchi N; Ohta T; Oh JE; Kim YH; Kleihues P; Ohgaki H
    Acta Neuropathol; 2013 Dec; 126(6):931-7. PubMed ID: 23955565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TERT promoter hot spot mutations are frequent in Indian cervical and oral squamous cell carcinomas.
    Vinothkumar V; Arunkumar G; Revathidevi S; Arun K; Manikandan M; Rao AK; Rajkumar KS; Ajay C; Rajaraman R; Ramani R; Murugan AK; Munirajan AK
    Tumour Biol; 2016 Jun; 37(6):7907-13. PubMed ID: 26700669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TERT Promoter Mutation Spatial Heterogeneity in a Metastatic Follicular Thyroid Carcinoma: Implications for Clinical Work-Up.
    Stenman A; Hysek M; Jatta K; Bränström R; Darai-Ramqvist E; Paulsson JO; Wang N; Larsson C; Zedenius J; Juhlin CC
    Endocr Pathol; 2019 Sep; 30(3):246-248. PubMed ID: 31154561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.
    Liu T; Wang N; Cao J; Sofiadis A; Dinets A; Zedenius J; Larsson C; Xu D
    Oncogene; 2014 Oct; 33(42):4978-84. PubMed ID: 24141777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TERT promoter hotspot mutations in breast cancer.
    Shimoi T; Yoshida M; Kitamura Y; Yoshino T; Kawachi A; Shimomura A; Noguchi E; Yunokawa M; Yonemori K; Shimizu C; Kinoshita T; Ichimura K; Fukuda T; Fujiwara Y; Tamura K
    Breast Cancer; 2018 May; 25(3):292-296. PubMed ID: 29222734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas.
    Gao K; Li G; Qu Y; Wang M; Cui B; Ji M; Shi B; Hou P
    Oncotarget; 2016 Feb; 7(8):8712-25. PubMed ID: 26556853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telomerase Reverse Transcriptase Promoter Mutations in Human Hepatobiliary, Pancreatic and Gastrointestinal Cancer Cell Lines.
    Hirata M; Fujita K; Fujihara S; Mizuo T; Nakabayashi R; Kono T; Namima D; Fujita N; Yamana H; Kamada H; Tani J; Kobara H; Tsutsui K; Matsuda Y; Ono M; Masaki T
    In Vivo; 2022; 36(1):94-102. PubMed ID: 34972704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of human telomerase reverse transcriptase promoter region mutations C228T and C250T for overall survival in spinal chordomas.
    Bettegowda C; Yip S; Jiang B; Wang WL; Clarke MJ; Lazary A; Gambarotti M; Zhang M; Sciubba DM; Wolinsky JP; Goodwin CR; McCarthy E; Germscheid NM; Sahgal A; Gokaslan ZL; Boriani S; Varga PP; Fisher CG; Rhines LD
    Neuro Oncol; 2019 Aug; 21(8):1005-1015. PubMed ID: 30976795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma.
    Gandolfi G; Ragazzi M; Frasoldati A; Piana S; Ciarrocchi A; Sancisi V
    Eur J Endocrinol; 2015 Apr; 172(4):403-13. PubMed ID: 25583906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.